Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W F Bennett

Showing results (101-110 of 119) with videos related to

Pageof 12
Sort By:
Urology|July 1, 1992
Computed tomography of primary transitional cell carcinoma of upper urinary tractsR A Badalament, W F Bennett, J G Bova, et al.
Circulation|November 15, 1995
New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPAC R Benedict, C J Refino, B A Keyt, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1993
Optimized thrombolysis of cerebral clots with tissue-type plasminogen activator in a rabbit model of embolic strokeG R Thomas, H Thibodeaux, W F Bennett, et al.
Kidney International|December 14, 1999
Compensatory renal growth in uninephrectomized adult mice is growth hormone dependentA Flyvbjerg, W F Bennett, R Rasch, et al.
AJR. American Journal of Roentgenology|July 20, 2002
MR cholangiopancreatography in patients with primary sclerosing cholangitis: interobserver variability and comparison with endoscopic retrograde cholangiopancreatographyK M Vitellas, A El-Dieb, K K Vaswani, et al.
The Journal of Biological Chemistry|March 15, 1991
High resolution analysis of functional determinants on human tissue-type plasminogen activatorW F Bennett, N F Paoni, B A Keyt, et al.
Thrombosis and Haemostasis|August 2, 1993
A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogenC J Refino, N F Paoni, B A Keyt, et al.
Stroke|October 1, 1994
A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleedingG R Thomas, H Thibodeaux, C J Errett, et al.
Thrombosis and Haemostasis|June 1, 1996
Limiting systemic plasminogenolysis reduces the bleeding potential for tissue-type plasminogen activators but not for streptokinaseG R Thomas, H Thibodeaux, C J Errett, et al.
The Journal of Clinical Endocrinology and Metabolism|June 18, 1999
Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GHM O Thorner, C J Strasburger, Z Wu, et al.
Pageof 12

Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Urology|July 1, 1992
Computed tomography of primary transitional cell carcinoma of upper urinary tractsR A Badalament, W F Bennett, J G Bova, et al.
Circulation|November 15, 1995
New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPAC R Benedict, C J Refino, B A Keyt, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1993
Optimized thrombolysis of cerebral clots with tissue-type plasminogen activator in a rabbit model of embolic strokeG R Thomas, H Thibodeaux, W F Bennett, et al.
Kidney International|December 14, 1999
Compensatory renal growth in uninephrectomized adult mice is growth hormone dependentA Flyvbjerg, W F Bennett, R Rasch, et al.
AJR. American Journal of Roentgenology|July 20, 2002
MR cholangiopancreatography in patients with primary sclerosing cholangitis: interobserver variability and comparison with endoscopic retrograde cholangiopancreatographyK M Vitellas, A El-Dieb, K K Vaswani, et al.
The Journal of Biological Chemistry|March 15, 1991
High resolution analysis of functional determinants on human tissue-type plasminogen activatorW F Bennett, N F Paoni, B A Keyt, et al.
Thrombosis and Haemostasis|August 2, 1993
A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogenC J Refino, N F Paoni, B A Keyt, et al.
Stroke|October 1, 1994
A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleedingG R Thomas, H Thibodeaux, C J Errett, et al.
Thrombosis and Haemostasis|June 1, 1996
Limiting systemic plasminogenolysis reduces the bleeding potential for tissue-type plasminogen activators but not for streptokinaseG R Thomas, H Thibodeaux, C J Errett, et al.
The Journal of Clinical Endocrinology and Metabolism|June 18, 1999
Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GHM O Thorner, C J Strasburger, Z Wu, et al.
Pageof 12